{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"vip-gabapentin","urls":{"read":"https://miscsubjects.com/api/articles/vip-gabapentin/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/vip-gabapentin/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/vip-gabapentin/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/vip-gabapentin/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/vip-gabapentin/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/vip-gabapentin/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/vip-gabapentin/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"vip-gabapentin","title":"VIP Peptide Evidence for Gabapentin Users: Immune and Autonomic Layers","register":"source_ledger","tags":["peptide","matrix"],"updated_at":"2026-07-17T02:43:23.642Z","body_excerpt":"## What's breaking down if you have Gabapentin / pregabalin\n\nGabapentin and pregabalin primarily act on voltage-gated calcium channels to reduce excitatory neurotransmitter release. This leads to dampened nerve signaling in conditions involving neuropathic pain or hyperexcitability. The drug suppresses pain signals without addressing underlying nerve tissue integrity or inflammatory states that may contribute to ongoing issues. If autonomic regulation or immune balance plays a role in your experience with these medications, that layer remains unaddressed by the drug itself.\n\nDegeneration here centers on sustained nerve hyperexcitability and potential secondary inflammatory contributions rather than direct mechanical breakdown. Repair pathways would focus on modulating immune responses and autonomic tone to support tissue homeostasis instead of ongoing signal suppression.\n\n## Why VIP might help you\n\n1. You are reading about Gabapentin / pregabalin — what breaks down matters before any compound name.\n2. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\nVIP acts on VPAC1 and VPAC2 receptors expressed in immune cells and autonomic nerves. This binding can shift cytokine profiles toward lower pro-inflammatory markers in lab models. If your situation involves immune overactivation alongside nerve signaling changes addressed by gabapentin, VIP's receptor activity offers a distinct path focused on restoring balance rather than blocking calcium influx.\n\nIn this framing, VIP supports autonomic nerve function through vasodilation and smooth muscle regulation observed in multiple tissue types. The result could complement signal suppression by addressing a separate layer of tissue-level regulation.\n\n## Why Gabapentin / pregabalin matters for you\n\nDrug: Gabapentin / pregabalin\nWhat it does: Masks neuropathic pain signal; does not repair nerve.\nTherefore for you: This drug suppresses a signal. Suppression can reduce immediate load on daily function but trades off against repair by leaving the underlying nerve and immune environment unchanged. Long-term reliance on signal masking may allow degenerative processes in those layers to continue unchecked.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- VIP → immune / autonomic\n\nVIP's immune and autonomic actions address a layer separate from gabapentin's calcium channel effects. The combination in principle allows signal reduction while supporting repair-oriented modulation. No overlapping mechanisms are claimed here.\n\n## What the evidence actually shows\n\nPreclinical studies in mice demonstrate VIP reduces incidence and severity of collagen-induced arthritis through suppression of inflammatory mediators (source s5 from web:5 and web:12). This is an animal model of autoimmune joint inflammation, not neuropathic pain or gabapentin use. Human data on VIP for similar immune layers remain limited to observational or small infusion studies unrelated to gabapentin.\n\nA randomized clinical trial in healthy volunteers tested VIP infusion for headache provocation and found modest effects on cranial hemodynamics (source s11 from web:11). This human study does not address gabapentin users or nerve repair.\n\nOne human study measured lower VIP levels in patients with primary pulmonary hypertension compared to controls (source s16 from web:16). This is mechanistic observation, not a trial of VIP administration for pain or gabapentin contexts.\n\nNo human trials directly examine VIP alongside gabapentin or pregabalin. Claims linking the two remain mechanistic or speculative.\n\n## What scientists say\n\nReviews describe VIP as a neuropeptide with anti-inflammatory and immunomodulatory properties in preclinical settings, including regulation of NF-κB signaling (source s6 from web:6 and web:14). Researchers not","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c1","text":"VIP reduces incidence and severity of collagen-induced arthritis in mice via inflammatory mediator suppression.","tier":"preclinical","weight":0.5,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s5"],"source_status":"sourced","why_material":"Establishes preclinical immune modulation layer separate from pain signal suppression.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.5,"quote_gated":false},{"id":"c5","text":"VIP shows anti-inflammatory effects in mouse arthritis models but no direct human neuropathic pain trials exist.","tier":"preclinical","weight":0.5,"section":"What we do not know","slot":null,"interaction_risk":false,"status":"active","source_ids":["s5"],"source_status":"sourced","why_material":"Highlights evidence gap for the specific cross.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.5,"quote_gated":false},{"id":"c4","text":"Gabapentin and pregabalin inhibit α2δ subunit-containing voltage-dependent calcium channels.","tier":"mechanistic","weight":0.3,"section":"Why Gabapentin / pregabalin matters for you","slot":null,"interaction_risk":false,"status":"active","source_ids":["s28"],"source_status":"sourced","why_material":"Confirms signal suppression mechanism without repair.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"c2","text":"A randomized trial showed VIP infusion produces modest cranial hemodynamic effects in healthy volunteers.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s11"],"source_status":"sourced","why_material":"Provides the main human trial data point on VIP administration.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c3","text":"Lower VIP levels observed in primary pulmonary hypertension patients versus controls.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s16"],"source_status":"sourced","why_material":"Mechanistic observation of VIP in a disease state.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"s5","type":"review","url":"https://www.hopkinsarthritis.org/arthritis-news/vasoactive-intestinal-peptide-vip-prevents-experimental-arthritis-news-summary-from-johns-hopkins-arthritis/","title":"Vasoactive intestinal peptide (VIP) prevents experimental arthritis","quote":"Mice treated with VIP showed delayed onset, lower incidence and decreased severity of CIA in comparison with placebo-treated arthritic mice.","summary":"Summary of mouse collagen-induced arthritis study with VIP treatment.","claim_ids":["c1","c5"],"link_status":"ok","quote_status":"verified","hash":"4b8df224853aaf574bf8ccc9390d77e1241d85e346b0206a44cd89b6ac6d255e"},{"id":"s11","type":"clinical_trial","url":"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2782759","title":"Effect of Vasoactive Intestinal Polypeptide on Development of Headache and Associated Symptoms","quote":"This randomized clinical trial examines whether a 2-hour infusion of vasoactive intestinal polypeptide provokes migraine attacks.","summary":"Human RCT on VIP infusion effects in volunteers.","claim_ids":["c2"],"link_status":"http_403","quote_status":"unverified","hash":"905248284b1db39c86392540792543ce8e8e500f9a9e4f0f3461a6a21513fd0a"},{"id":"s16","type":"pubmed","url":"https://www.jci.org/articles/view/17500","title":"Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension","quote":"VIP level in normal subjects (n = 45) was 42.4 ± 17.1 pg/ml. ... VIP levels in the group of PPH patients (n = 12) were at the detection threshold of the assay (i.e., 10 pg/ml).","summary":"Human measurement of VIP levels in disease vs controls.","claim_ids":["c3"],"link_status":"ok","quote_status":"unverified","hash":"d1572ea2abfd3790b628fc8f2e3a13b0096e4602f6e1188c16a9f3753ce6c148"},{"id":"s28","type":"other","url":"https://x.com/PharmaFactz/status/1176592633847844870","title":"Mechanism of Pregabalin / Gabapentin","quote":"both drugs act as inhibitors of α2δ subunit-containing voltage-dependent calcium channels (VDCCs).","summary":"Explanation of gabapentin/pregabalin mechanism.","claim_ids":["c4"],"link_status":"ok","quote_status":"verified","hash":"560971eff23a043f8f1d1de97578db1a20a0f8d6d4dad48f68480d116d483743"}],"anecdotal_sources":[],"scientific_sources":[{"id":"s5","type":"review","url":"https://www.hopkinsarthritis.org/arthritis-news/vasoactive-intestinal-peptide-vip-prevents-experimental-arthritis-news-summary-from-johns-hopkins-arthritis/","title":"Vasoactive intestinal peptide (VIP) prevents experimental arthritis","quote":"Mice treated with VIP showed delayed onset, lower incidence and decreased severity of CIA in comparison with placebo-treated arthritic mice.","summary":"Summary of mouse collagen-induced arthritis study with VIP treatment.","claim_ids":["c1","c5"],"link_status":"ok","quote_status":"verified","hash":"4b8df224853aaf574bf8ccc9390d77e1241d85e346b0206a44cd89b6ac6d255e"},{"id":"s11","type":"clinical_trial","url":"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2782759","title":"Effect of Vasoactive Intestinal Polypeptide on Development of Headache and Associated Symptoms","quote":"This randomized clinical trial examines whether a 2-hour infusion of vasoactive intestinal polypeptide provokes migraine attacks.","summary":"Human RCT on VIP infusion effects in volunteers.","claim_ids":["c2"],"link_status":"http_403","quote_status":"unverified","hash":"905248284b1db39c86392540792543ce8e8e500f9a9e4f0f3461a6a21513fd0a"},{"id":"s16","type":"pubmed","url":"https://www.jci.org/articles/view/17500","title":"Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension","quote":"VIP level in normal subjects (n = 45) was 42.4 ± 17.1 pg/ml. ... VIP levels in the group of PPH patients (n = 12) were at the detection threshold of the assay (i.e., 10 pg/ml).","summary":"Human measurement of VIP levels in disease vs controls.","claim_ids":["c3"],"link_status":"ok","quote_status":"unverified","hash":"d1572ea2abfd3790b628fc8f2e3a13b0096e4602f6e1188c16a9f3753ce6c148"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"vip-gabapentin","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":5,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":5,"claims_total":5,"sources":4,"anecdotal":0,"scientific":3,"user_reports":0,"questions":0,"evidence_ingests":0}}